Deciphera Pharmaceuticals LLC is a drug manufacturers - specialty & generic business based in the US. Deciphera Pharmaceuticals LLC shares (DCPH) are listed on the NASDAQ and all prices are listed in US Dollars. Deciphera Pharmaceuticals LLC employs 355 staff and has a trailing 12-month revenue of around $174.9 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $13.25 - $25.61 |
|---|---|
| 50-day moving average | $21.67 |
| 200-day moving average | $15.94 |
| Wall St. target price | $27.52 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.21 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
| Revenue TTM | $174.9 million |
|---|---|
| Gross profit TTM | $-62,555,000 |
| Return on assets TTM | -26.62% |
| Return on equity TTM | -50.37% |
| Profit margin | -108.87% |
| Book value | $3.85 |
| Market Capitalization | $2.2 billion |
TTM: trailing 12 months
We're not expecting Deciphera Pharmaceuticals LLC to pay a dividend over the next 12 months.
Over the last 12 months, Deciphera Pharmaceuticals LLC's shares have ranged in value from as little as $13.25 up to $25.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Deciphera Pharmaceuticals LLC's is 0.184. This would suggest that Deciphera Pharmaceuticals LLC's shares are less volatile than average (for this exchange).
Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Access remote advice, planning and portfolio management from this established financial services company.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2025.
A deep dive into the highlights and limitations of Robinhood.
This account boasts commission-free trades and no minimums but has a low cash sweep rate.